CDC data released today shows that overall, the nation is on the right trajectory in decreasing the number of new HIV diagnoses with a marked decrease in new cases among young people. At the same time, while usage of PrEP, which are drugs that prevent HIV, significantly increased, it mostly benefited Whites, while the wide disparities in uptake for Blacks, Latinos, and women persisted.
The HIV+Hepatitis Policy Institute, Diabetes Leadership Council, Diabetes Patient Advocacy Coalition, and three patients filed their reply in support of their motion for summary judgment in the U.S. District Court for the District of Columbia in their ongoing lawsuit against copay accumulators. The suit challenges HHS’s 2021 Notice of Benefit and Payment Parameters rule, which permits insurance plans to refuse to credit copay assistance from drug manufacturers toward beneficiaries’ deductibles and out-of-pocket maximums.
While not surprised by Judge O’Connor’s decision, which will immediately impact coverage of HIV testing, hepatitis B and C testing, along with PrEP, it is imperative that these critical preventive services must continue for the health of our nation. We expect that the U.S. government will quickly act to stay this decision so that preventive services can continue nationwide, and appeal it.
“President Biden’s budget is yet another demonstration of his leadership in ending HIV. He recognizes the historic role the federal government must play, and the investments needed to end infectious diseases, such as HIV and hepatitis C,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Now, it is essential that Congress works together to ensure it maintains the federal government’s commitment to ending HIV and at the same time, invests the necessary resources to end hepatitis. We also must guard against any erosion in funding of these programs, as some have proposed,” continued Schmid.
Yesterday, 29 patient, provider, and consumer organizations representing a wide range of illnesses and health conditions filed an amicus brief in support of a case brought against the U.S. Department of Health and Human Services by the HIV+Hepatitis Policy Institute, the Diabetes Leadership Council, the Diabetes Patient Advocacy Coalition, and three patients. Filed in the U.S. District Court for the District of Columbia, the lawsuit challenges the federal 2021 Notice of Benefit and Payment Parameters rule, which allows health insurers to avoid counting the value of drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations. Plaintiffs recently filed a motion for summary judgment, asserting that the rule violates cost-sharing requirements mandated by the Affordable Care Act and is also arbitrary and capricious.